Neuropsychiatric complications of antiretroviral therapy

Drug Safety

Volumn 29, Issue 10, 2006, Pages 865-874

  Cespedes, Michelle S ^a,b   Aberg, Judith A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

AGITATION; ANHEDONIA; ANXIETY DISORDER; AUDITORY HALLUCINATION; CATATONIA; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONFUSION; DELUSIONAL DISORDER; DEPRESSION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG POTENCY; GRANDIOSE DELUSION; HALLUCINATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MANIA; MENTAL DISEASE; MIGRAINE; MOOD CHANGE; MUTISM; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SUICIDAL IDEATION;

ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG MONITORING; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 33749426630     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629100-00004     Document Type: Review

References (60)

1. Palella FJ, Delaney KM, Moorman AC, et al. The Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
2. Mauri MC, Fabiano L, Bravin S, et al. Schizophrenic patients before and after HIV infection: a case-control study. Encephale 1997; 23 (6): 437-41
3. Sewell DD, Jeste DV, Atkinson JH, et al. HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioural Research Center Group. Am J Psychiatry 1994; 151 (2): 237-42
4. Dube B, Benton T, Cruess DG, et al. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30 (4): 237-46
5. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am Psychiatry 2001 May; 158 (5): 725-30
6. Blanch J, Martinez E, Rousaud A, et al. Preliminary data of prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001; 27 (4): 336-43
7. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000; 182: 599-602
8. Langford D. Chronic exposure of the blood-brain barrier to highly active antiretroviral therapy. Infect Dis Clin Pract 2004; 12: 158-62
9. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171-7
10. Berger JR, Nath A, Greenberg RN, et al. Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 2000; 54 (4): 921-6
11. Zheng J, Ghorpade A, Niemann D, et al. Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia. J Virol 1999; 73: 8256-67
12. Enting RH, Hoetelmans RM, Lange JM, et al. Antiretroviral drugs and the central nervous system. AIDS 1998 Oct 22; 12 (15): 1941-55
13. Langford D, Grigorian A, Hurford R, et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. Neuropathol Exp Neurol 2004; 63: 1038-47
14. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41: 1787-93
15. Kandanearatchi A, Vyakarnam A, Landau S, et al. Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors. Neurovirol 2004; 10: 136-9
16. Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis 2003; 37: 1107-11
17. Marra C, Sinha S, Evans S, et al. ACTG 736: CSF HIV-1 and Cognitive Function in Individuals receiving potent ART [abstract no. 361]. Denver (CO): 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8;
18. Maxwell S, Scheftner WA, Kessler HA, et al. Manic syndrome associated with zidovudine. JAMA 1988; 259 (23): 3406-7
19. O'Dowd MA, McKegney F. Manic syndrome associated with zidovudine [letter]. JAMA 1988; 260 (24): 3587
20. Schaerf FW, Miller R, Pearlson GD, et al. Manic syndrome associated with zidovudine [letter]. JAMA 1988; 260 (24): 3587-8
21. Colebunders R, Hilbrands R, De Roo A, et al. Neuropsychiatric reaction induced by abacavir. Am J Med 2002; 113: 616
22. Foster R, Olajide D, Everall IP. Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Med 2003; 4: 139-44
23. Foster R, Taylor C, Everall IP. More on abacavir-induced neuropsychiatric reactions. AIDS 2004; 18 (18): 2449
24. Wise MEJ, Mistry K, Reid S. Neuropsychiatric complications of nevirapine treatment. BMJ 2002; 324: 879
25. Colebunders R, Florence E. Neuropsychiatric reaction induced by clarithromycin. Sex Transm Infect 2002; 78: 75-6
26. Peyriere H, Mauboussin JM, Rouanet I, et al. Management of sudden psychiatric disorders related to efavirenz. AIDS 2001; 15: 1323-4
27. Shah MD, Balderson K. A manic episode associated with efavirenz therapy for HIV infection. AIDS 2003; 17 (11): 1713-4
28. Blanch J, Corbella B, Garcia F, et al. Manic syndrome associated with efavirenz overdose. Clin Infect Dis 2001; 33: 270-1
29. Moreno A, Labelle C, Samet JH. Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases. HIV Med 2003; 4: 302-4
30. Hasse B, Gunthard F, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005; 40: e22-3
31. de la Garza CL, Paoletti-Duarte S, Garcia-Martin C, et al. Efavirenz induced psychosis. AIDS 2001; 15: 1911-2
32. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002; 22 (7): 930-3
33. GlaxoSmithKline. Retrovir (zidovudine) tablets, capsules, and syrup: prescribing information. Research Triangle park (NC): GlaxoSmithKline Company 2005 Nov.
34. Rachlis A, Fanning MM. Zidovudine toxicity. Clinical features and management. Drug Safety 1993; 8: 312-20
35. GlaxoSmithKline. Ziagen (abacavir) tablets and oral solution: prescribing information. Research Triangle Park (NC): GlaxoSmithKline Company 2006 Mar.
36. Prime K, French P. Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy (HAART). Sex Transm Infect 2001 Aug; 77 (4): 297-8
37. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002; 16: 1201-15
38. Abbott Laboratories. Norvir (ritonavir) capsules and oral solution: prescribing information. North Chicago (IL): Abbott Laboratories, 2006 Jan
39. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents - October 6, 2005. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services [online]. Available from URL: http://AIDSinfo.nih.gov [Accessed 2006 Sep 6]
40. Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001 Aug 1; 27 (4): 336-43
41. Goldenberg D, Boyle B. Psychiatric Safety of efavirenz [abstract WePeB4238]. Presented at the XIII Conference on AIDS. Durban, 2000 Jul 9-15
42. Puzantian T, Lee J, Lee RJ, et al. Psychiatric effects associated with efavirenz: a retrospective study [poster 481]. Presented at the 40th Annual Meeting of the Infectious Diseases Society of America. Chicago, 2002 Oct
43. Bristol-Meyers Squibb Company. Sustiva™ (efavirenz) cap-sules and tablets: prescribing information. Princeton (NJ): Bristol-Meyers Squibb Company, 2005 Feb
44. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1 infected patients treated with efavirenz versus protease inhibitor-containing regimen. J Acquir Immune Defic Syndr 2002; 29: 244-53
45. Ribaudo H, Clifford D, Gulick R, et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s [oral abstract no. 132]. San Francisco (CA): 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11
46. Lucas GM, Gebo K, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16: 767-74
47. Mocroft A, Madge S, Johnson A, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy, response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22: 369-85
48. Hirschel B, Flepp M, Bucher H, et al. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerability among risk groups: a case control study from the Swiss HIV cohort. AIDS 2002; 16: 381-5
49. Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV infected individuals with a history of substance abuse. HIV Clin Trails 2003; 4 (3): 145-9
50. Halman M. Management of depression and related neuropsychiatric symptoms associated with HIV/AIDS and antiretroviral therapy. Can J Infect Dis 2001; 12: 9C-19C
51. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180 (3): 862-4
52. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71-5
53. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400
54. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42: 401-7
55. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trail Group Study 398. Antimicrob Agents Chemother 2003; 47 (1): 130-7
56. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15 (1): 1-5
57. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38 (5): 560-5
58. Lochet P, Peyriere H, Lotthe A, et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4: 62-4
59. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143: 714-21
60. Giancola ML, Lorenzini P, Balestra P, et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 41: 332-7